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Abstract
Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell 
non-Hodgkin’s lymphomas (T-NHL) that display distinct clinical and biological 
features. Despite a detailed understanding of PTCL transformation, there is no 
current accepted standard of care for newly diagnosed or relapsed/refractory (r/r) 
patients. PTCL are highly proliferative neoplasms with an immunosuppressive 
microenvironment that elaborates drug resistance to current therapies with poor 
outcomes. Aurora kinases (AKs) are a family of mitotic oncogenic serine/threonine 
kinases (A, B/C) that are aberrantly expressed in PTCL, providing a growth advan-
tage. Alisertib, an AK-A inhibitor, blocks the mitotic phase of the cell cycle resulting 
in apoptosis. Preclinical and clinical trials in PTCL demonstrated an ~30% response 
rate in r/r PTCL similar to other investigational agents. In order to improve response 
rates, alisertib-based combination therapies were tested with HDAC inhibitors, 
romidepsin and vorinostat, in phase Ib trials. To improve response rates to alisertib, 
we evaluated alisertib-induced polyploidy as a drug resistance mechanism by 
targeting microtubules with vincristine. In addition, we also targeted immunosup-
pression-induced proliferation with an anti-PD-L1 antibody and PI3K inhibition in 
PTCL. Targeting aberrant proliferation and immunosuppression is a novel strategy 
that warrants evaluation in clinical trials for PTCL, an unmet clinical need.
Keywords: peripheral T-cell lymphoma, aurora kinases, aurora kinase inhibitors, 
immune therapy, targeted therapy
1. Introduction
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphopro-
liferative disorders that comprise ~10% of non-Hodgkin’s lymphomas (NHL) [1]. 
PTCL is classified into at least 19 different subtypes affecting precursor T cells or 
mature post-thymic T cells with the cell of origin, an activated memory CD44+ T 
cell [2]. Approximately 60% of PTCL diagnoses fall into one of the four subtypes 
[e.g., peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, 26%), 
anaplastic large-cell lymphoma (ALCL, ALK+ 7%, ALK- 6%), angioimmuno-
blastic T-cell lymphoma (AITL, 19%), and enteropathy T-cell lymphoma (<5%)] 
[3]. Frontline anthracycline-based therapies (e.g., CHOP-like) utilized in diffuse 
large B-cell lymphoma (DLBCL) provide inferior outcomes to PTCL (NOS) and 
ALCL-ALK- versus ALCL-ALK+ disease [4]. Further, for CD30+ PTCL (19/26 
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ALCL), frontline brentuximab vedotin + CHP had a 92% complete response rate 
with an estimated 5-year PFS and OS rates of 52 and 80%, respectively, suggestive 
of an treatment option that is curative for some patients with CD30+ PTCL [5]. In 
addition, for young fit chemosensitive patients in the relapse setting, HD therapy 
followed by auto-SCT may be curative in a small proportion of patients [6].
PTCL patients with refractory or relapsed disease should be encouraged to par-
ticipate in clinical trials with novel investigational agents [7]. USFDA has approved 
four drugs as single agents: pralatrexate (an antifolate), romidepsin and belinostat 
(histone deacetylase [HDAC] inhibitors), and brentuximab vedotin (anti-CD30 
Mab-ADC). Several agents have demonstrated antitumor activity with response 
rates of 10–30% (e.g., gemcitabine, bendamustine, duvelisib, copanlisib, alisertib, 
mogamulizumab) [8]. Preclinical studies with novel agents support combina-
tions that target cell proliferation and immune suppression which are expected to 
enhance degree, depth, and duration of responses in PTCL. Here, we review novel 
aurora kinase inhibitor-based combination therapies for PTCL (Figure 1).
2. Aurora kinases
The aurora kinases (Aks) are a family of serine/threonine kinases that regulates 
multiple aspects of cell division and proliferation through the mitotic (M) phase 
of the cell cycle. They play an essential role in progression through the cell cycle 
during mitosis and meiosis in ensuring error-free chromosome arrangement around 
assembly of the mitosis spindle, centrosome alignment and separation, and cyto-
kinesis [9–12]. AKs are composed of three highly conserved isoforms, aurora A, B, 
and C, which share substantial similarity in sequence and structure in their catalytic 
domain but are diverse in N-terminal domain sequence, subcellular localization, 
and functions [13, 14]. AKs A and B are ubiquitously expressed in normal tissues, 
whereas AK C is specifically expressed in the testis, where it functions primarily in 
Figure 1. 
Aurora kinase-based combination therapy for PTCL (modified from Mahadevan et al. [63]). Inhibition of 
aurora A kinase (e.g., alisertib) activates PI3K signaling in PTCL which in turn enhances the induction of 
PD-L1. Cytokine signaling through the MAPK pathway also induces PD-L1 expression leading to profound 
immune suppression in PTCL. Targeting mitosis with alisertib and immune suppression with an anti-PD-L1 
antibody leads to a highly synergistic combination in a syngeneic mouse model of PTCL [52]. Targeting mitosis 
with alisertib plus vincristine is synergistic causing mitotic catastrophe. This combination is synthetic lethal 
when combined with anti-PD-L1 plus PI3K inhibition [52]. Further, Aurora A kinase inhibition combined 
with histone deacetylase inhibitors is also synergistic implicating epigenetic modulation.
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spermatogenesis [13, 15]. AK A localizes primarily at centrosomes, spindle poles, 
and later on the spindle midzone, where it recruits the cyclin B1-CDK1 complex 
and promotes the cell to mitotic entry and exit, centrosome separation and matura-
tion, and bipolar spindle assembly [9, 11, 16–18]. Inhibition of AK A causes defects 
in chromosome segregation and maturation, mitotic spindle aberrations, non-
diploidy, cell cycle arrest, and apoptosis [15, 19, 20].
AK B is referred to as a chromosomal passenger protein and, along with other 
regulatory proteins, constitutes the chromosome passenger complex [13, 15, 16]. 
This complex concentrates at centrosomes and the central spindle, then relocal-
izes to the midzone to ensure proper chromosome alignment and segregation and 
spindle assembly, and regulates cytokinesis [12, 13, 15, 16]. Inhibition of AK B inter-
feres with normal chromosomal alignment during mitosis and leads to inhibition of 
histone H3 phosphorylation, cytokinesis failure, and polyploidization [15, 21].
AK C concentrates in the centrosomes and shares interacting proteins and 
functional overlap with AK B during mitosis, although its primary role is in meiosis, 
where it is necessary for efficient spermatogenesis [22]. With similar structural and 
localization properties, its functions may be redundant or cooperative to those of 
AK B [22].
2.1 Role of aurora kinases in tumorigenesis
AKs A and B are frequently amplified in many epithelial tumors, cancers of solid 
organs, and hematological malignancies, with elevated levels of mRNA and protein 
present in tumors [11, 19]. Amplification of the chromosomal region that encodes 
AURKA has been linked to high levels of expression of AK A in a wide range of tumor 
types, and strong expression of the AURKB gene is observed in many tumor types 
[20]. AK A overexpression is sufficient to transform NIH/3T3 cells in vitro, which 
then induced tumors when transplanted into nude mice [12]. In addition, increased 
risk of breast, non-small cell lung, esophageal, and ovarian cancer is associated with 
the AURKA Phe3IIle polymorphism [18]. Furthermore, aberrant AK A expression 
may contribute to cancer cell survival through activities that enhance NF-kB, mTOR, 
Raf1, Myc, Wnt, or AKT signaling pathways [23]. Because AK A interacts with p53 at 
multiple levels, cancer cells with a deficient p53-p21Waf1/Cip1 postmitotic checkpoint 
function may be more susceptible to AK inhibition [18, 24].
AK overexpression is also associated with a mitogenic phenotype and genetic 
instability [25, 26]. Resulting tumor cell non-diploidy contributes to uncontrolled 
cell cycle progression and promotes cell survival. These effects are synergistic with 
histone deacetylases in regulating cell proliferation and survival through activa-
tion of AKT/mTOR signaling in lymphomas [27]. AK C is overexpressed in several 
cancers and cancer cell lines, but its role in carcinogenesis and effect on tumor cell 
proliferation is unclear [28, 29]. Similar to AK B, overexpressed AK C binds to and 
localizes with the IAP protein survivin in mitotic cells [15, 27]. However, a clear role 
for AK C in tumorigenesis has not been identified.
2.2 Role of aurora kinases in drug resistance
Drug resistance remains a major challenge in oncology, regardless of whether 
cancer resistance to drug therapy is de novo and/or acquired. Elevated AK A and B 
expression is associated with chemoresistance in multiple tumor types and to differ-
ent classes of anticancer drugs [30–39]. AK A has been implicated in the develop-
ment of resistance and reduced sensitivity to microtubule-targeted chemotherapy 
[11, 31, 40–42]. Elevated levels override the spindle assembly checkpoint (SAC) 
responsible for monitoring defective mitotic spindle formation, thus conferring 
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resistance to paclitaxel-induced apoptosis [42]. Similarly, there was a dose-depen-
dent association between AK B expression in cell lines and resistance to paclitaxel 
[43]. AK activity also contributes to resistance to platinum-containing agents, and 
sensitivity to these drugs in vitro can be restored by AK inhibition [30, 38, 44]. These 
mechanisms present a potential opportunity to inhibit AK to restore or enhance 
drug sensitivity, which has been demonstrated preclinically [23]. This strategy holds 
implications for combination therapies with AK inhibitors and their potential role 
for relapsed/refractory malignancies including PTCL.
3. Aurora kinase inhibition in PTCL
Given the poor clinical outcomes associated with PTCL, more effective treat-
ments informed by a better understanding of PTCL biology are needed. Several 
subtypes of PTCL have shown to overexpress AK A and B [45–47], making them 
an attractive therapeutic target. CD8+ T cells expressing STAT5BN642H, the most 
frequent STAT5B mutation found in patients with leukemias and lymphomas, were 
exquisitely sensitive to AK inhibition in a transgenic mouse model [48]. Given their 
role in multiple oncogenic processes, inhibition of AKs has a potential of halting 
malignant progression in PTCL.
Multiple preclinical and clinical studies have been conducted to explore the role 
of AK inhibitors in the treatment of advanced PTCL. Small molecules designed to 
bind competitively and reversibly to the ATP-binding pocket have been developed 
for all three AKs, including isoform-specific and pan-AK inhibitors [15, 21, 49]. AK 
isoform selectivity and inhibitory activity differ among individual agents. However, 
it is unclear whether a strategy of selective or pan-AK inhibition will provide 
superior efficacy [15, 19] without compromising safety.
3.1 Preclinical studies involving aurora kinase inhibitors
AK inhibitors were first studied in solid organ tumors and in hematologic tumor 
cell lines other than PTCL. Agents that have undergone preclinical evaluation in 
lymphomas are listed in Table 1. Much focus has been on AK A inhibition, as the 
mechanism of AK B in cancer is less clear.
Alisertib is a potent inhibitor of AK A, with a half maximal inhibitory concen-
tration (IC50) value of 1.2 nmol/L [50]. It has less activity against AK B, with an IC50 
value of 396.5 nmol/L. Alisertib was studied in colorectal cancer and non-Hodgkin’s 
lymphoma tumor cell lines in vivo and in vitro. In vitro, alisertib showed inhibi-
tion of proliferation in tumor cell lines, more so for lymphoma cell lines. In vivo, 
alisertib caused tumor growth inhibition (TGI) of 43.3, 84.2, and 94.7% when 
given at doses of 3, 10, and 30 mg/kg, respectively, in nude mice with subcutaneous 
colorectal HCT-116 cell. In a non-Hodgkin’s lymphoma model ONI-LY19, there was 
tumor regression (TR) when alisertib was given at doses of 20 and 30 mg/kg [50]. 
Based on preliminary data from this study and similar preclinical studies of solid 
organ and hematological malignancies, phase I clinical trials involving alisertib in 
r/r PTCL were conducted.
The first preclinical study of alisertib involving PTCL cell lines was conducted 
by Qi et al. [47]. In this in vitro study, alisertib was tested on two mouse PTCL cell 
lines, TIB-48 and CRL-2396. AK A contributes to autophosphorylation on Thr288 in 
the activation loop. Alisertib at 0.1 μM completely inhibited AK A autophosphory-
lation on Thr288. Analysis of DNA content with flow cytometry showed that 
treatment of both PTCL cell lines with alisertib at 0.5, 1, and 1.5 μM resulted in cell 
cycle arrest in G2/M phase and there was evidence of endoreduplication resulting in 
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polyploidy. These changes led to dose-dependent apoptosis of both cell lines when 
alisertib was used at 100 nM or higher.
Zullo et al. studied the cytotoxic effects of alisertib in vivo [51]. In addition, the 
effects of various combination drug regimens involving alisertib in vitro and in vivo 
on cell lines of r/r TCL were also studied. Alisertib alone showed concentration and 
strong time-dependent cytotoxicity with the lowest IC50 value achieved at 72 hours 
noted to be 60–1000 nm/L. Alisertib (IC10–IC30) given along with romidepsin 
(IC10–IC20) had a synergistic interaction in vitro in eight different TCL cell lines 
following 72 hours of drug exposure [51]. The greatest interaction was seen in 
C5MJ, an alisertib-resistant ATLL HTLV-1 Tax+ cell line. This combination induced 
polyploidy in all TCL cell lines after 48 hours of treatment. There was also evidence 
of increased apoptosis with approximately 13 and 52% of cells showing apoptosis 
with increasing concentrations of alisertib (50 nmol/L and 100 nm/L) used. In 
this same trial, in vivo analysis with this combination regimen was conducted on 
a xenograft model using HH cell lines of TCL. The combination drug regimen 
was statistically superior compared to single agent alone and control group cohort 
(dimethyl sulfoxide) in decreasing the mean tumor burden over time (p < 0.05) 
and in prolonging the survival in mice (p < 0.05) by day 58. Drug concentration 
analysis in the animals inside the tumors showed that concentration of alisertib in 
the combination tumor samples increased at 1 (400 vs. 100 nmol/L) and 6 hours 
(300 vs. 150 nmol/L) compared to tumor samples in mice where drug was given 
alone. These data support synergistic cytotoxicity of a combination drug regimen 
of alisertib plus romidepsin [51]. In the same study, alisertib was also evaluated in 
combination with other drugs including pralatrexate or ixazomib, but there were no 
synergetic interactions in vitro in TCL cell lines.
Immunohistochemistry (IHC) analysis of tumor samples from patients treated 
with alisertib for r/r PTCL (SWOG 1108) showed a high Ki-67 and programmed 
death ligand (PD-L1): PD-1 staining ratio of 8.9-fold [52]. Increased levels of 
PD-L1 are associated with immune suppression. In view of this, Islam et al. 
conducted a study where alisertib was given along with PD-LI antibody (BE0101, 
Name Target (IC50 in 
vitro)
Sponsor Comments
AT9283 Aurora A 
(3 nM)
Aurora B 
(3 nM)
Astex Multikinase inhibitor, 
including JAK2, JAK3, Abl 
T3151, Flt3
AZD1152 
(barasertib)
Aurora A (1369)
Aurora B 
(0.37 nM)
AstraZeneca
Chiauranib Aurora B 
(0.37 nM)
Chipscreen Biosciences Multikinase inhibitor, 
including VEGFRs, c-KIT, and 
PDGFRs
MLN8237 
(alisertib)
Aurora A 
(1.2 nM)
Aurora B 
(396.5 nM)
Takeda/millennium 
Pharmaceuticals
Aurora A
TAK-901 Aurora A 
(21 nM)
Aurora B 
(15 nM)
Takeda Pan-Aurora
Table 1. 
Aurora kinase inhibitors studied for lymphomas (from: Refs. [15, 20, 49, 60]).
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Bio X Cell, NH) in mice with r/r PTCL xenografts (CRL-2396 cells) [52]. Since the 
pan-PI3K inhibitor (PF-04691502) inhibits expression of the PD-L1 along with 
vincristine, these were also added to the former drug combination, and the results 
were compared between the two groups. Alisertib given alone resulted in tumor 
growth regression of ~30%, whereas PD-L1 antibody given alone had no anti-
PTCL activity. Alisertib plus PD-L1 antibody resulted in ~90% TGI, but 20% of 
mice had a relapse at 2 weeks and 50% mice relapsed at 4 weeks. The combination 
of alisertib plus PD-L1 antibody plus pan-PI3K inhibitor and vincristine showed a 
100% TGI. Only 25% of mice had recurrence at 4 weeks after discontinuation of 
treatment. It was noted that the OS with the four-drug regimen (p < 0.0001) was 
statistically superior to the two-drug combination.
3.2 Clinical trials involving aurora kinase inhibitors
AK A inhibitors have been studied in clinical trials after antitumor activity was 
shown in multiple in vitro and in vivo studies (Table 2). In two phase I trials by 
Cervantes et al. (n = 59) and Dees et al. (n = 87) in patients with advanced solid 
organ malignancies, the maximum tolerated dose of alisertib was 50 mg twice 
a day for 7 days in a 21-day cycle [53, 54]. Similarly, in another phase I study by 
Kelly et al. (n = 58), alisertib was evaluated in patients with multiple relapsed/
refractory hematologic malignancies (multiple myeloma, non-Hodgkin’s lym-
phoma and chronic lymphocytic leukemia) [55]. In this study there were two 
patients with advanced PTCL. Just as with the other phase I studies, this study 
also determined that the MTD for alisertib was 50 mg twice a day for 7 days. The 
drug pharmacokinetics was also studied, with the terminal elimination half-life 
noted to be 19.5 hours. The safety analysis showed that most frequent grade 3 or 
greater adverse effects were hematological in nature including neutropenia (45%), 
thrombocytopenia (28%), anemia (19%), and leukopenia (19%). One patient with 
PTCL experienced a PR.
Given the promising outcomes of alisertib in preclinical studies and previous 
phase I clinical trials, phase II trials were conducted for PTCL patients [56, 57]. In 
one such study by Friedberg et al. (n = 48), alisertib was given to patients with mul-
tiple hematological malignancies (diffuse large B-cell lymphoma, mantle cell lym-
phoma, transformed follicular lymphoma, Burkitt’s lymphoma, non-cutaneous T-cell 
lymphoma) at a dose of 50 mg twice a day for 7 days in 21-day cycles. This study 
included eight patients with advanced PTCL. Four of eight patients (ORR = 50%) 
with advanced PTCL showed a clinical response (CR/PR). Three patients that 
showed response continued to be in remission and had received alisertib for greater 
than 1 year at the time of publication of the study [57]. In the phase II study by Barr 
et al. (n = 37) patients with various subtypes of r/r PTCL (PTAL, NOS (n = 13), 
AITL (n = 9), adult T-cell leukemia/lymphoma (n = 4), anaplastic large-cell lym-
phoma (n = 2), extra nodal natural killer/T-cell lymphoma (n = 2), and transformed 
mycosis fungoides (n = 7)) received alisertib at the RP2D. In patients with PTCL, the 
ORR was 30% (CR = 7%, PR = 23%). The long-term outcomes were reported for the 
whole group and not reported for PTCL subtypes. The median PFS time was noted 
to be 3 months with a 1-year PFS rate of 8%. The median OS was determined to be 
8 months, with OS at 1 year estimated to be 30% for the entire group. The long-term 
outcomes in this study could have been negatively biased because none of patients 
with transformed mycosis fungoides showed any clinical response with alisertib. As 
seen in the phase I studies, the most common grade 3 or higher adverse effects were 
due to myelosuppression (neutropenia 32%, anemia 30%, thrombocytopenia 24%). 
Common non-hematologic adverse effects included fatigue (50%), alopecia (24%), 
and mucositis (20%) [56].
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Author Phase No. of patients MTD Response EFS/PFS OS SE (>grade 3)
Kelly et al. [55] I 2 50 mg bid for 7 days PR = 50% NL NL Neutropenia = 9%
Gi side affects
Alopecia
Friedberg et al. [57] II 8 NR ORR = 50% 1 yr. = 75% 1 yr. = 75% Neutropenia = 63%
Leukemia = 54%
Anemia = 35%
Thrombocytopenia = 33%
Stomatitis = 15%
Fatigue = 6%
Barr et al. [56] II 30 NR ORR = 30%
CR = 7%
PR = 23%
NLS NLS Neutropenia = 32%
Anemia = 30%
Thrombocytopenia = 24%
O’Connor et al. [58] III A = 120
C = 118
NR ORR A = 33%
ORR C = 43%
mPFS A = 3.7 m
mPFS M = 3.4 m
mOS A = 9.9 m
mOS M = 12.2 m
Grade 3 A ≥ 85%
Grade 3 M ≥ 81%
Abbreviations: No., number; MTD, maximum tolerated dose; NR, not reached; PR, partial remission; ORR, overall response rate; CR, complete remission; EFS, event free survival; PFS, progression-free 
survival; SE, side effects; NL, not listed; NLS, not listed separately for alisertib; mPFS, median progression-free survival; mOS, median overall survival; A, alisertib; M, monotherapy; SE(>grade 3), greater 
than grade 3 side effects; yr. = year.
Table 2. 
Clinical trials of alisertib in treatment of relapsed/refractory PTCL.
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Based on good tolerance and positive response/survival seen in patients with 
advanced PTCL in multiple phase I and II studies with alisertib, an international 
phase III randomized controlled study was conducted [58]. In this study, patients 
with r/r PTCL received either enteric-coated alisertib (n = 120) at a dose of 50 mg 
twice a day for 7 days in a 21-day cycle or investigator’s choice of monotherapy 
treatment (n = 118) using pralatrexate, romidepsin, or gemcitabine. The treatment 
was intended to be continued until disease progression, unacceptable toxicity, or for 
2 years. An interim analysis showed that ORR, median PFS, and median OS were 
33%, 3.7 months, and 9.9 months versus 43%, 3.3 months, and 12.2 months, respec-
tively, with alisertib and investigator’s choice of treatment. The rate of grade 3 or 
higher side effects was 85% for alisertib and 81% for the investigator’s treatment 
choice. Since the interim analysis of this phase III study failed to show superior out-
comes of alisertib compared to investigator’s preferred choice of drugs, a decision 
was made by the investigators to discontinue the study.
Given the promise of combination regimen with alisertib given along with another 
drug that is generally used for patients with r/r PTCL in preclinical studies, phase I 
clinical studies with some of these regimens are in progress. In one such phase I study 
by Strati et al., alisertib plus romidepsin in patients with PTCL (n = 3) or aggressive 
B-cell lymphoma (n = 16) [59] showed that the drug combination was well tolerated 
with most common grade 3–4 side effects due to myelosuppression. One patient with 
PTCL showed a CR and other two patients showed stable disease. The enrollment 
for the highest dose for these regimens is ongoing. Similarly, in another phase I study, 
vorinostat plus alisertib is being evaluated for patients with r/r PTCL (NCT01567709).
4. Conclusion and future directions
PTCLs are highly aggressive clinically challenging diseases, with high rates of 
relapse, and poor overall survival with traditional cell cycle directed anti-lymphoma 
therapies. Effective treatment options are limited for patients with newly diagnosed 
and r/r PTCL. AKs are aberrantly expressed and active in PTCL, leading to uncon-
trolled cell division, immune suppression, and oncogenesis. AK inhibition leads to 
catastrophic errors of mitosis, such as defective cytokinesis, misaligned centrosomes, 
and mitotic spindle malformation, culminating in apoptosis [60, 61]. However, 
drug-resistant non-diploid cells can enter the cell cycle by reductive divisions during 
intermittent therapy [62]. Several AK inhibitors have been studied preclinically and 
clinically in trials for patients with r/r PTCL. Despite showing benefit in phase II stud-
ies, an interim analysis of a phase III trial of alisertib, a selective AK inhibitor, failed to 
show improved response or survival rates compared to standard of care single-agent 
monotherapy for patients with r/r PTCL. However, targeting cell proliferation plus 
immune suppression in preclinical studies of novel combinations of alisertib plus a 
PD-L1 inhibitor plus a pan-PIK3 inhibitor plus vincristine as well as combined HDAC 
inhibition plus alisertib shows synergistic activity and prolonged survival in mouse 
models of PTCL. Furthermore, AK inhibition may improve or restore tumor sensitivity 
to anticancer agents, particularly microtubule-targeted and platinum-containing drugs 
in the context of pathogenic TP53 mutant status. Continued clinical studies of novel 
drug combinations with AK inhibitors are warranted to target not only malignant T 
cells but also their immune suppressive T cells residing in the tumor microenvironment.
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